MedTrace Logo

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

NCT05275439 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2026-03-18

Study results available
· View outcomes & findings →

Summary

SL03-Old Hundred(OHD)-104 is designed as a Phase 1a/1b open label, trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of SL-172154 monotherapy as well as in combination with azacitidine or in combination with Azacitidine and Venetoclax.

Conditions

Interventions

DRUG

SL-172154

The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.

DRUG

Azacitidine (AZA)

Chemotherapy drug approved for use in MDS and AML.

DRUG

Venetoclax

Drug approved for use in AML.

Sponsors & Collaborators

  • Shattuck Labs, Inc.

    lead INDUSTRY

Principal Investigators

  • Shattuck Labs · Shattuck Labs

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-17
Primary Completion
2025-02-06
Completion
2025-02-06
FDA Drug
Yes

Countries

  • United States
  • Canada
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05275439 on ClinicalTrials.gov